Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions (NYSE: EBS) operates at the intersection of biodefense preparedness and public health response, making its news flow distinct from typical pharmaceutical companies. As a primary supplier of medical countermeasures to the U.S. government, Emergent's announcements often reflect government contract awards, procurement decisions, and emergency preparedness initiatives rather than conventional drug development pipelines.
News coverage for Emergent BioSolutions typically centers on government contracts from agencies like BARDA and the Strategic National Stockpile, FDA regulatory decisions for biodefense products, international customer agreements for medical countermeasures, and developments in the company's naloxone product line addressing the opioid crisis. Manufacturing updates from the company's specialized biologics facilities and CDMO operations also feature prominently.
The biodefense sector generates news tied to public health preparedness budgets, outbreak response needs, and geopolitical considerations around biological threats. Emergent's position as a key supplier means its announcements often coincide with government funding cycles and emergency preparedness policy decisions. The company's dual focus on government biodefense contracts and commercial naloxone products creates two distinct news streams for investors to monitor.
Track Emergent BioSolutions news on Stock Titan to follow government contract announcements, FDA regulatory decisions, earnings releases, and strategic developments affecting this biodefense-focused life sciences company.
Emergent BioSolutions (NYSE: EBS) received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax (Anthrax Vaccine Adsorbed) in 2026. The order is placed under Emergent’s existing IDIQ contract W911SR24D0001, led by the Capability Program Executive CBRND in collaboration with the Defense Health Agency. Deliveries will occur in 2026 and the order includes a one-year base period plus two option periods covering 2027 and 2028. The company said the award continues its partnership to provide anthrax vaccination for military personnel at elevated risk.
Emergent BioSolutions (NYSE: EBS) agreed to provide additional financial support to continue the Africa CDC-led MpOx Study in Africa (MOSA), a double-blind, platform-adaptive clinical trial launched in 2024 to evaluate treatments for mpox.
An independent data and safety monitoring board completed an initial safety review in December 2025 after 50 patients were randomized and recommended continuation with no safety concerns identified. Africa CDC and PANTHER plan to extend MOSA to additional countries, including a site in Uganda, and enroll more patients toward the next milestone.
The release notes there is currently no dedicated antiviral therapy for mpox and cites Africa CDC case totals of 61,383 confirmed cases and 296 deaths across 32 countries since 2024.
Emergent BioSolutions (NYSE: EBS) announced that Joe Papa, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 PM PST. An audio link to the session will be available and kept live for up to 30 days. The company said its presentation slides will be posted on the Investors section of the Emergent website at the time of the presentation.
Emergent BioSolutions (NYSE: EBS) announced that the U.S. FDA approved its supplemental BLA on Dec 12, 2025 to add the company's Winnipeg, Canada facility as a drug product manufacturing and testing site for raxibacumab, a monoclonal antibody for treatment and prophylaxis of inhalational anthrax.
The Winnipeg site is described as USMCA-compliant with over 45 years of therapeutics manufacturing experience and capabilities for drug substance, fill/finish, and analytical testing. The approval follows a May 2024 operational plan to consolidate manufacturing in Winnipeg and Lansing as part of a multi-year transformation strategy.
Emergent BioSolutions (NYSE: EBS) marks the 10-year anniversary of the U.S. FDA approval of NARCAN® Nasal Spray, the first FDA‑approved nasal naloxone spray for emergency opioid overdose treatment, originally approved in November 2015 and later authorized OTC in March 2023.
The company highlights milestones: >85 million doses distributed since 2016, the 2018 acquisition of Adapt Pharma, launch of NARCANDirect, Project NEXUS real‑world evidence efforts, and product extensions including wall unit kits and convenience kits. Emergent cites a nearly 32% decline in opioid overdose deaths reported by CDC in 2024 and reaffirms commitment to naloxone access.
Emergent BioSolutions (NYSE: EBS) announced that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14, 2025 after 19 years of service.
Dr. Sullivan joined the board in 2006 and most recently served as chair of the compensation committee and as a member of the nominating and corporate governance committee. The company noted his experience in healthcare, government and biotechnology and cited his role guiding decisions during Emergent’s multi-year transformation. Dr. Sullivan previously served as president of Morehouse School of Medicine and as Secretary of the Department of Health and Human Services.
Emergent BioSolutions (NYSE: EBS) reported Q3 2025 total revenue $231.1M, beating the high end of guidance by $21.0M. Q3 net income was $51.2M (margin 22%) and adjusted EBITDA was $87.8M (margin 38%).
The company noted adjusted gross margin 61% (up 200 bps YoY), sequential naloxone revenue growth led by NARCAN nasal spray, and raised full-year 2025 revenue and profitability guidance. Emergent reported 11 MCM contract modifications/orders in 2025 and that international customers represent 34% of MCM orders YTD. Year-to-date revenue was $594.2M, down versus prior year.
Emergent BioSolutions (NYSE: EBS) released a survey of ~250 U.S. policy opinion leaders on Oct 28, 2025 showing heightened concern about biological threats and U.S. preparedness.
Key findings: 65% say the likelihood of a biological attack is rising, 45% say the U.S. is unprepared, 73% believe a biological attack would be easier to carry out than a nuclear one, and nearly 90% support continued U.S. leadership and government backing for biotech/biodefense. Emergent highlighted its >25 years of countermeasure experience and North American BSL‑2/3 manufacturing capabilities for anthrax, botulism, smallpox and viral hemorrhagic fevers.
Emergent BioSolutions (NYSE: EBS) will report third quarter 2025 financial results and host a conference call on Wednesday, October 29, 2025 at 5:00 PM ET. The call will be available live via webcast and by telephone with advance registration; registered telephone participants receive a confirmation email with dial-in numbers, a unique passcode, and registrant ID. A replay will be accessible on the company’s Investors page.
Emergent BioSolutions (NYSE:EBS) has reaffirmed its commitment to combating the opioid crisis through awareness, education, and expanded naloxone access during several September observances. The company offers two key products: NARCAN® Nasal Spray 4 mg (first FDA-approved over-the-counter opioid overdose reversal treatment) and KLOXXADO® Nasal Spray 8 mg.
The company is actively engaging with partners like the National Safety Council to increase workplace access to naloxone. Emergent recently received the Green Cross for Safety Advocate Award alongside Amazon for their efforts to expand naloxone availability in workplaces. The company is also supporting various initiatives including SOAR West Virginia Save a Life Day and Truth Pharm's National Trail of Truth event.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
